Richard Hopkins
Follow
Get notifications in MyBN when activity occurs.
Richard Hopkins
Richard Hopkins is a founder of Phylogica and had been the chief executive since July 2013; he announced his resignation in July 2016. He then became chief executive of PharmAust Pharmaceutical for a year before becoming chief executive and managing director of Zelira Therapeutics in July 2018. He left Zelira in May 2021 following a strategic consolidation by the company to have its leadership team based in the US.
His most recent research was focused on engineering peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications.
His most recent research was focused on engineering peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 367th | Advanced Braking Technology | 23% | 29% |
| 636th | PYC Therapeutics | 3% | 27% |
| 806th | DTI Group | -5% | -15% |
| 1278th | K2fly | -37% | -8% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 87th |  | PYC Therapeutics | $15.8m |
| 90th |  | GreenHy2 | $15.0m |
| 91st | | K2fly | $14.8m |
| 93rd | | Advanced Braking Technology | $14.7m |
| 94th | | DTI Group | $13.3m |
201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in BlinkLab shares soar on ASX debut | 04 Apr 2024 |
| REMUNERATION UPDATE: Managing Director, Zelira Therapeutics | 02 Nov 2020 |
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Managing Director | | 2018 - 2021 | 155 |
| Chief Executive Officer | | 2017 - 2018 | 128 |
| Co-Founder, Chief Executive | | 2013 - 2016 | 87 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Zelira Therapeutics | 23 Dec 2019 | Issued | 12,500,000 | $0.00 | $1,250 | OtherIssue of securities: 12,500,000 - performance rights. |
| PYC Therapeutics | 30 Jun 2016 | Other | 504,262 | OtherOptions expired | ||
| PYC Therapeutics | 14 Aug 2015 | Issued | 9,222,510 | $0.01 | $92,225 | Rights issue |
| PYC Therapeutics | 14 Aug 2015 | Issued | 2,777,490 | $0.01 | $27,775 | Rights issue |
| PYC Therapeutics | 24 Dec 2014 | Issued | 6,500,000 | OtherIssue of options |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 02/07/15 | PYC Therapeutics | Entitlement offer | $10.0m | >> |
| 03/08/20 | Zelira Therapeutics | Placement | $8.8m | >> |
| 05/02/20 | Zelira Therapeutics | Placement | $4.6m | >> |
| 06/12/17 | PharmAust | Placement | $1.8m | >> |
